L3VLUP
ProSign in

IQV · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

IQVLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • IQV
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterIQVLLY
Q3 202021 holders, $4.8bn33 holders, $14.1bn
Q4 202022 holders, $5.2bn29 holders, $17.3bn
Q1 202118 holders, $5.4bn24 holders, $23.0bn
Q2 202126 holders, $6.1bn24 holders, $27.8bn
Q3 202124 holders, $5.9bn31 holders, $29.9bn
Q4 202124 holders, $6.9bn31 holders, $34.7bn
Q1 202221 holders, $5.2bn24 holders, $35.3bn
Q2 202215 holders, $3.9bn33 holders, $42.7bn
Q3 202221 holders, $3.1bn31 holders, $43.4bn
Q4 202219 holders, $3.9bn31 holders, $46.6bn
Q1 202324 holders, $4.4bn33 holders, $44.3bn
Q2 202323 holders, $5.5bn37 holders, $59.6bn
Q3 202322 holders, $5.4bn44 holders, $67.6bn
Q4 202314 holders, $6.2bn45 holders, $73.6bn
Q1 202415 holders, $6.9bn41 holders, $95.3bn
Q2 202420 holders, $5.8bn43 holders, $110bn
Q3 202423 holders, $6.3bn45 holders, $107bn
Q4 202422 holders, $5.7bn46 holders, $93.9bn
Q1 202522 holders, $5.1bn42 holders, $98.4bn
Q2 202521 holders, $5.4bn43 holders, $93.2bn
Q3 202517 holders, $5.9bn39 holders, $86.7bn
Q4 202518 holders, $7.0bn41 holders, $123bn
Q1 202611 holders, $4.7bn39 holders, $106bn
Q2 202619 holders, $5.3bn44 holders, $132bn
IQV

Iqvia HLDGS Inc

Holders
17
Reported value
$5.9bn
Buyers
11
Sellers
9

Breadth +2 among 95 comparable managers.

Health care services and researchHealthcare: biopharma and medtech · L3VLUP
LLY

Eli Lilly & Co

Holders
39
Reported value
$86.7bn
Buyers
22
Sellers
22

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2025

Among the 44 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only IQV (5)

Appaloosa LP, ExodusPoint Capital Management LP, Farallon Capital Management LLC, Glenview Capital Management LLC, Markel Group Inc

Only LLY (27)

Acadian Asset Management LLC, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, Freestone Grove Partners LP, GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, Polen Capital Management LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Verition Fund Management LLC, and 2 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →